ProKidney Corp. (NASDAQ:PROK) Given Average Rating of “Moderate Buy” by Analysts

Shares of ProKidney Corp. (NASDAQ:PROK) have been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $7.40.

A number of brokerages have issued reports on PROK. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of ProKidney in a research note on Monday, May 18th. Jefferies Financial Group upgraded ProKidney to a “strong-buy” rating in a research note on Wednesday, March 18th. Wall Street Zen lowered ProKidney from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, April 21st.

ProKidney Price Performance

NASDAQ:PROK opened at $1.85 on Friday. The firm has a market capitalization of $558.81 million, a price-to-earnings ratio of -3.49 and a beta of 1.64. ProKidney has a one year low of $0.54 and a one year high of $7.13. The business has a fifty day moving average price of $1.84 and a 200-day moving average price of $2.08.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, equities research analysts expect that ProKidney will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProKidney

A number of institutional investors have recently bought and sold shares of PROK. R Squared Ltd purchased a new stake in ProKidney in the 1st quarter worth $25,000. SummitTX Capital L.P. purchased a new stake in ProKidney in the 1st quarter worth $26,000. Cetera Investment Advisers purchased a new stake in ProKidney in the 4th quarter worth $28,000. AQR Capital Management LLC increased its stake in ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after buying an additional 27,098 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of ProKidney during the fourth quarter valued at about $65,000. Hedge funds and other institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.